Western pharmaceutical companies have agreed to slash the prices of dozens of drugs in China, as the industry tries to strengthen its foothold in the world’s second-largest drug market.
Anglo-Swedish drugmaker AstraZeneca, Gilead of the US, France’s Sanofi and Switzerland’s Roche are among the multinationals that have agreed with Beijing to cut the prices of 70 drugs by more than 60 per cent on average in return for their inclusion in a state-run insurance scheme.
The cuts will affect several top-selling medicines, including Adalimumab, an arthritis treatment sold by US drugmaker AbbVie under the brand Humira.
您已閱讀20%（615字），剩余80%（2394字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。